164 related articles for article (PubMed ID: 22312942)
1. Unpredicted adverse reaction to omalizumab.
Jandus P; Hausmann O; Haeberli G; Gentinetta T; Mueller U; Helbling A
J Investig Allergol Clin Immunol; 2011; 21(7):563-6. PubMed ID: 22312942
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
[TBL] [Abstract][Full Text] [Related]
3. Mastocytosis and insect venom allergy.
Bonadonna P; Zanotti R; Müller U
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
Sokol KC; Ghazi A; Kelly BC; Grant JA
J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
Palgan K; Bartuzi Z; Gotz-Zbikowska M
Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab and hypersensitivity reactions.
Shankar T; Petrov AA
Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
[TBL] [Abstract][Full Text] [Related]
7. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.
Galera C; Soohun N; Zankar N; Caimmi S; Gallen C; Demoly P
J Investig Allergol Clin Immunol; 2009; 19(3):225-9. PubMed ID: 19610266
[TBL] [Abstract][Full Text] [Related]
8. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
9. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
[TBL] [Abstract][Full Text] [Related]
10. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.
Bonadonna P; Gonzalez-de-Olano D; Zanotti R; Riccio A; De Ferrari L; Lombardo C; Rogkakou A; Escribano L; Alvarez-Twose I; Matito A; Vega A; Passalacqua G
J Allergy Clin Immunol Pract; 2013; 1(5):474-8. PubMed ID: 24565619
[TBL] [Abstract][Full Text] [Related]
11. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose.
Stretz E; Oppel EM; Räwer HC; Chatelain R; Mastnik S; Przybilla B; Ruëff F
Clin Exp Allergy; 2017 Dec; 47(12):1631-1639. PubMed ID: 28802075
[TBL] [Abstract][Full Text] [Related]
12. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
White KM; England RW
Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
[TBL] [Abstract][Full Text] [Related]
13. Hymenoptera venom immunotherapy and field stings.
Lang R; Hawranek T
J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy: A report of three cases.
Droitcourt C; Ponvert C; Dupuy A; Scheinmann P; Abou-Taam R; de Blic J; Lezmi G
Allergol Int; 2019 Apr; 68(2):268-269. PubMed ID: 30342888
[No Abstract] [Full Text] [Related]
15. Basophil sensitivity in patients not responding to venom immunotherapy.
Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of basophil activation in mastocytosis with Hymenoptera venom anaphylaxis.
González-de-Olano D; Alvarez-Twose I; Morgado JM; Esteban López MI; Vega Castro A; Díaz de Durana MD; Sánchez-Muñoz L; Matito A; de la Hoz Caballer B; Sanz ML; Orfao A; Escribano L
Cytometry B Clin Cytom; 2011 May; 80(3):167-75. PubMed ID: 21520404
[TBL] [Abstract][Full Text] [Related]
17. Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis.
Gruzelle V; Ramassamy M; Bulai Lidiveanu C; Didier A; Mailhol C; Guilleminault L
Allergy; 2018 Nov; 73(11):2260-2263. PubMed ID: 29984458
[No Abstract] [Full Text] [Related]
18. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.
Gülsen A; Ruëff F; Jappe U
Allergol Select; 2021; 5():128-132. PubMed ID: 33733040
[TBL] [Abstract][Full Text] [Related]
19. Hymenoptera venom allergy.
Ebo DG
Verh K Acad Geneeskd Belg; 2007; 69(4):213-30. PubMed ID: 17821959
[TBL] [Abstract][Full Text] [Related]
20. Mastocytosis and Hymenoptera venom allergy.
Ruëff F; Placzek M; Przybilla B
Curr Opin Allergy Clin Immunol; 2006 Aug; 6(4):284-8. PubMed ID: 16825870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
